All updates
All updates
today 46BioPharma Dive评分6464
BioSpace精选评分7171 Argenx shutters Sjogren's study, losing blockbuster expansion opportunity for Vyvgart
中文产业新闻Chinese source评分6060 《Cell》发表糖萼编辑MSC首个人体I期试验：单次输注使晚期骨质疏松患者骨折风险降94%
中文产业新闻Chinese source评分6767 司普奇拜单抗治疗中重度结节性痒疹Ⅲ期24周数据在EADV 2026公布
中文产业新闻Chinese source评分6262 BMJ发表III期试验：脐带间充质干细胞降低心梗后心衰风险
中文产业新闻Chinese source评分5959 伏美替尼一线治疗 EGFR exon20ins NSCLC 的 III 期 FURVENT 试验未达主要终点，ArriVent 当日股价跌 52%
BioSpace精选评分6262 Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold
STAT News评分6868 STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease
中文产业新闻Chinese source评分6666 ImmunoPRISM二期：特立妥单抗对比Rd在高危冒烟型骨髓瘤2年PFS率92%对比49%
中文产业新闻Chinese source评分6161 2026 IGCS丨程文俊教授解读ALTER-GO-010最新数据：安罗替尼联合化疗一线治疗晚期卵巢癌中位PFS达27.43个月
BioSpace精选评分6161 Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers
中文产业新闻Chinese source评分6767 西格列汀联合ATG方案显著降低替代供者移植后急性GVHD
中文产业新闻Chinese source评分5858 艾力斯伏美替尼FURVENT三期试验未达主要终点
社区讨论（Reddit）评分5151 A randomised trial (405 UK families) showed that giving 2-year-olds the live attenuated nasal flu vaccine doubled the odds of pneumococcal acquisition among household contacts at 14 days, linked pneumococcal carriage density; effects were no longer significant by day 28.
中文产业新闻精选Chinese source评分7474 苏大附一院牵头III期RCT登JCO：西格列汀预防移植后急性GVHD排异风险降一半
中文产业新闻精选Chinese source评分7171 艾力斯伏美替尼FURVENT III期三期试验未达PFS主要终点触发跌停
NEJM评分4242 Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
NEJM评分5050 A Multicomponent Intervention to Improve Maternal Infection Outcomes
NEJM精选评分7171 Optogenetic Therapy for Restoring Aspects of Visual Function
监管与产业动态精选评分6262 Two medications demonstrated comparable results in treating compulsive sexual behavior disorder
监管与产业动态精选评分6363 Intranasal sufentanil-ketamine appears safe, effective for pediatric acute pain
监管与产业动态评分1616 Signal or noise? > Gene therapy can partly restore sight in blind people, researchers reveal - The Guardian >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #pharma #competitivemarketing
中文产业新闻Chinese source评分3434 Arrowhead：INHBE siRNA启动MASH二期临床
中文产业新闻Chinese source评分3434 再生元：重启cMET ADC项目
中文产业新闻精选Chinese source评分7878 礼来Retatrutide TRIUMPH-2试验：肥胖合并2型糖尿病患者80周减重超20%、40%血糖恢复正常
监管与产业动态评分2424 68Ga-DOTATATE PET/CT Detection of Hypertrophic Osteoarthropathy in a Pediatric Patient With Neuroblastoma Following Anti-GD2 Immunotherapy
The Lancet Oncology精选评分5555 [Articles] Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial
中文产业新闻Chinese source评分2828 默沙东启动多拉韦林/伊拉曲韦针对HIV-1感染儿科患者的II期临床试验
中文产业新闻Chinese source评分3535 恒瑞医药启动瑞康芦泽妥塔单抗联合阿得贝利单抗治疗可切除非小细胞肺癌的中国Ⅱ期临床试验
STAT News精选评分5454 STAT+: In small trial, optogenetics restores some vision lost to retinitis pigmentosa
中文产业新闻精选Chinese source评分6363 AiCuris在TANDEM会议公布pritelivir治疗免疫低下患者难治性HSV感染的关键3期数据
中文产业新闻精选Chinese source评分7979 Vaxcyte 31价肺炎球菌结合疫苗 VAX-31 三期 OPUS-1 头对头辉瑞与默沙东达全部主要终点
中文产业新闻Chinese source评分6363 艾力斯伏美替尼FURVENT III期未达PFS主要终点
中文产业新闻Chinese source评分6464 伏美替尼全球III期FURVENT研究未达PFS主要终点，艾力斯出海路径承压
临床试验登记评分2323 TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma
临床试验登记评分2121 Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)
临床试验登记评分3333 Biomarker-guided Reduction of Immunosuppression in Liver Transplant Recipients (BRITRE)
临床试验登记评分3232 Immunogenicity and Safety of Two Respiratory Syncytial Virus Vaccine Strategies in Lung and Allogeneic Haematopoietic Stem Cell Transplant Recipients: A Phase 2 Trial
临床试验登记评分2222 Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)
临床试验登记评分3333 An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.